

## W claim:

1. A selective binding partner for 5-HT<sub>5</sub> receptors, whose  
5 binding affinity for 5-HT<sub>5</sub> receptors is greater than for one  
or more 5-HT receptors other than 5-HT<sub>5</sub>.
2. A binding partner as claimed in claim 1, whose binding  
affinity for 5-HT<sub>5</sub> receptors is greater than for 5-HT<sub>1D</sub>  
10 and/or 5-HT<sub>1B</sub> receptors.
3. A binding partner as claimed in claim 1 or 2, which  
competitively inhibits the binding of 5-CT to 5-HT<sub>5</sub>  
15 receptors.
4. A binding partner as claimed in one of claims 1 to 3, wherein  
the K<sub>i</sub> values for its binding to 5-HT<sub>5</sub> receptors is less than  
10<sup>-8</sup> M, preferably less than 10<sup>-9</sup> M and in particular less  
than 10<sup>-10</sup> M.
5. A binding partner as claimed in one of claims 1 to 4, wherein  
its binding to 5-HT<sub>5</sub> receptors stimulates GTP binding to  
G proteins.
- 25 6. A binding partner as claimed in one of claims 1 to 5, wherein  
its binding to 5-HT<sub>5</sub> receptors brings about an increase in  
the intracellular calcium level.
7. A binding partner as claimed in one of claims 1 to 6, wherein  
30 its binding to 5-HT<sub>5</sub> receptors brings about an induction of  
phospholipase C activity.
8. A binding partner as claimed in one of claims 1 to 7, wherein  
its binding to 5-HT<sub>5</sub> receptors brings about an induction of  
35 cAMP production.
9. A pharmaceutical composition comprising at least one binding  
partner as claimed in one of claims 1 to 8 and a  
pharmaceutically tolerable excipient and, if appropriate,  
40 other active compounds.
10. The use of a binding partner for 5-HT<sub>5</sub> receptors for  
producing an agent for the treatment of cerebrovascular  
disorders.

11. The use as claimed in claim 10 for the treatment of migraine, in particular for the acute treatment of migraine.
12. The use as claimed in claim 10 or 11 of a binding partner as  
5 claimed in one of claims 1 to 8.
13. A process for the determination of the affinity of binding partners for 5-HT<sub>5</sub> receptors, where the binding partner is  
10 brought into contact with cell systems having 5-HT<sub>5</sub> receptors and the binding affinity is determined.
14. A process for the determination of the activity of binding partners for 5-HT<sub>5</sub> receptors, where the binding partner is  
15 brought into contact with cell systems having 5-HT<sub>5</sub> receptors and at least one binding partner-induced agonistic action is determined.
15. A process as claimed in claim 14, where the binding of GTP to G proteins, intracellular calcium levels, the phospholipase C  
20 activity and/or the cAMP production are determined.
16. A process as claimed in either claim 14 or 15, wherein human glioma cell lines or h5-HT<sub>5</sub>-transfected heterologous cell lines are used.  
25
17. A process as claimed in claim 16, wherein h5-HT<sub>5</sub>-transfected CHO cells, h5-HT<sub>5</sub>-transfected human kidney cells, or h5-HT<sub>5</sub>-transfected C-6 glioma cells are used.
- 30 18. An in vitro screening process for the identification of a 5-HT<sub>5</sub> receptor binding partner, where at least one process as claimed in claims 13 to 17 is used.

35

40

45